Related Experiment Video
Updated: Jun 28, 2026

MicroRNA In situ Hybridization for Formalin Fixed Kidney Tissues
Published on: November 30, 2013
A role for microRNA in cystic liver and kidney diseases
Andrew S Chu1, Joshua R Friedman
1Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Abstract:
The polycystic liver and kidney diseases are a family of disorders with heterogeneous etiologies. Proposed mechanisms of disease include ciliary dysfunction, excess cell proliferation, and altered cell-cell or cell-matrix interactions. In this issue of the JCI, Lee and colleagues provide data to support a novel mechanism for cystogenesis involving microRNA (miRNA) (see the related article beginning on page 3714). They demonstrate that levels of the miRNA miR15a are decreased in livers of patients with autosomal recessive and autosomal dominant polycystic kidney disease (ARPKD and ADPKD, respectively) and congenital hepatic fibrosis as well as in the PKC rat model of ARPKD. This results in increased expression of the cell-cycle regulator Cdc25A, which is a direct target of miR15a, and increased cellular proliferation and cystogenesis in vitro. These findings suggest that other miRNAs may also participate in the molecular pathogenesis of cystic liver and kidney diseases.
Insights
Decreased microRNA (miRNA) miR15a levels in polycystic liver and kidney diseases lead to increased cell proliferation and cyst formation. This discovery highlights a novel mechanism in the pathogenesis of these genetic disorders.
Area of Science:
- Genetics and Molecular Biology
- Cell Biology
- Developmental Biology
Background:
- Polycystic liver and kidney diseases encompass disorders with diverse causes.
- Previous research proposed mechanisms like ciliary dysfunction and altered cell interactions.
- The role of microRNAs in cystogenesis remained largely unexplored.
Discussion:
- Lee and colleagues identified a novel mechanism for cystogenesis involving microRNA (miRNA).
- They found decreased levels of miR15a in patients with polycystic kidney diseases and congenital hepatic fibrosis.
- This decrease was also observed in the PKC rat model of autosomal recessive polycystic kidney disease (ARPKD).
Key Insights:
- Reduced miR15a leads to elevated expression of the cell-cycle regulator Cdc25A.
- Cdc25A is a direct target of miR15a, indicating a regulatory relationship.
- Increased Cdc25A expression promotes cellular proliferation and cystogenesis in vitro.
Outlook:
- These findings suggest that miRNAs play a significant role in the molecular pathogenesis of cystic diseases.
- Further research may uncover other miRNAs involved in the development of polycystic liver and kidney diseases.
- This study opens new avenues for understanding and potentially treating these complex genetic disorders.
Related Concept Videos
MicroRNAs
MicroRNAs
MicroRNAs
Cirrhosis I: Introduction
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
